Home » About Us » Professor Thomas Borody

About Professor Thomas Borody

Professor Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 19871, which has saved hundreds of thousands of lives, and the Australian health system more than $10 billion in medical care and operations2.

Professor Borody founded the Centre for Digestive Diseases (CDD) in 1984 after a distinguished career with leading hospitals including St Vincent’s in Sydney and the Mayo Clinic in the USA.

He is a world-renowned leader in the clinical microbiota field dating back to 1988 when he started performing what is now called Fecal Microbiota Transplantation (FMT).

Professor Borody holds over 180 patents in areas such as; treatment of Helicobacter pylori, Crohn’s disease, bowel lavage, IBS and FMT.

Fecal Microbiota Transplantation (FMT)

As a practicing clinician leading the CDD in Australia, Professor Borody has overseen over 14,000 FMTs, creating a wealth of proprietary clinical data and insights.

Inflammatory disease and infection

In addition, Professor Borody has established novel therapies in the gastrointestinal field, including areas such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), Clostridium difficile Infection (CDI), parasite infestation, and resistant Helicobacter pylori 1.

Peer review

His knowledge and expertise are sought after by clinicians from around the world. He is a reviewer for leading medical journals including:

  • Journal of Clinical Gastroenterology
  • World Journal of Gastrointestinal Pharmacology and Therapeutics (Editorial Board)
  • American Journal of Gastroenterology
  • Journal of Digestive Diseases and Sciences
  • Journal of Endoscopy
  • Journal of Gastroenterology and Hepatology
  • Medical Journal of Australia
  • Journal of Digestive and Liver Diseases
  • Helicobacter

Biopharma founder

Professor Borody is also a scientific founder and scientific advisor to a number of biopharma companies.

References

1 Borody, T.J. (2016).  Development of novel therapies for gut dysbioses. Open Publications of UTS Scholars (OPUS). Identifier: http://hdl.handle.net/10453/52985

Link to thesis: https://opus.lib.uts.edu.au/bitstream/10453/52985/6/01front.pdf

2 Eslick,G.D., Tilden, D., Arora, N., Torres, M. & Clancy, R.L. (2020). Clinical and economic impact of “triple therapy” for Helicobacter pylori eradication on peptic ulcer disease in Australia. Helicobacter, 25(6).  Doi: 10.1111/hel.12751

Link to article: https://onlinelibrary.wiley.com/doi/epdf/10.1111/hel.12751

  1. PUBLICATIONS

    1.         Zhang F; Zhang T; Zhu H; Borody TJ. Evolution of fecal microbiota transplantation in methodology and ethical issues. Current Opinion in Pharmacology, 2019; 49:11-6. https://doi.org/10.1016/j.coph.2019.04.004
    2.         Wehrhahn M; Keighley C…; Borody TJ, et al. A series of three cases of severe Clostridium difficile infection in Australia associated with binary toxin producing clade 2 ribotype 251 strain. Anaerobe, 2019; 55:117-23.
    3.         Paramsothy S; Nielsen, S…Borody TJ, et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology, 2019; 156(5):1440-54.
    4.         Chamberlin W; Borody TJ. Comment on 2018 SCG Clinical Guideline: Antibiotics in Crohn’s Disease. The American Journal of Gastroenterology, 2018; Correspondence Published Online: 17 October 2018; https://doi.org/10.1038/s41395-018-0281-7
    5.         Paramsothy S; Kamm MA; …. Borody TJ, et al. Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis, Fusobacterium is Associated with Lack of Remission, while Metabolic Shifts to Starch Degradation and Short Chain Fatty Acid Production are Associated with Remission – Results from the Randomized Controlled Focus Study. Gastroenterology, 2018: 154 (6) S35.
    6.         Clancy A; Gunaratne AW…; Borody TJ, et al. Use of Lyophilised Microbiota Capsules for Fecal Microbiota Transplantation in Patients with Clostridium Difficile Infection. The American Journal of Gastroenterology, 2018; 113:S62.
    7.         Le Busque A; Gunaratne AW…; Borody TJ, et al. Anti-Protozoal Enema Treatment for Blastocystis Hominis and Dientamoeba Fragilis: Does volume matter? The American Journal of Gastroenterology, 2018; 113: S62-3.
    8.         Maistry P: Kim TJ…; Borody TJ, et al. Lyophilised Full Spectrum Microbiota Capsules for Treatment of Severe Clostridium Difficile Infection in 2 ICU patients: A Case Report. The American Journal of Gastroenterology, 2018; 113:S838
    9.         Kuenstner JT; Naser S; Chamberlin W; Borody TJ, et al. The Consensus from the Mycobacterium avium ssp. Paratuberculosis (MAP) Conference 2017. Front Public Health, 2017; 5:208. doi: 10.3389/fpubh.2017.00208. eCollection 2017.
    10.      Parasmsothy S; Kamm MA… Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. The Lancet, 2017; 389(10075): 1218-28.
    11.      Vivekanandarajah S; Jayewardene A…; Borody TJ, et al. The Efficacy of Liquid FMT in the Treatment of Symptoms Associated With Pos-Infectious IBS-A Retrospective Analysis. The American Journal of Gastroenterology, 2017; 112 (1): S-229.
    12.      De Zoysa P; Kingston-Smith H…; Borody TJ, et al. Treatment-Naive Ulcerative Colitis Patient Treated With Lyophilized Full Spectrum Microbiota: A Case Study. The American Journal of Gastroenterology, 2017; 112 (1): S-1095.
    13.      Borody TJ, et al; Colonoscopic Diagnostic Features of Stool and Mucosa of Inflamed versus Healed Ulcerative Colitis After Repeated FMT. The American Journal of Gastroenterology, 2017; 112 (1): S-1478.
    14.      Agrawal G; Langenberg P…; Borody TJ, et al. Prolonged Endoscopic Remission With Mucosal Healing in Crohn’s Patients: Treatment Cessation for 3-23 Years. The American Journal of Gastroenterology, 2017; 112 (1): S-420.
    15.      Kang DW; Adams JB; Gregory AC; Borody TJ, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome, 2017; 5(10):1-16 [Microbiome Editorial Team had selected your article as their nomination for inclusion in the “Change The World, One Article at a Time” collection]
    16.      Jaworski A; Borody TJ, et al. Antibiotic therapy for treatment-naïve Crohn’s disease patients. The American Journal of Gastroenterology, 2016; 111: S-272.
    17.      Borody TJ; Mitchell SW; Wong C; Jaworski A. Encapsulated lyophilized fecal microbiota therapy for the treatment of Clostridium difficile infection. The American Journal of Gastroenterology, 2016; 111: S-409.
    18.      Jaworski A; Mitchell SW… Borody TJ. FMT: How do alternate formats compare? The American Journal of Gastroenterology, 2016; 111: S-438.
    19.      Jaworski A; Mitchell SW… Borody TJ. Patient with relapsing C. difficile successfully treated with lyophilised encapsulated faecal microbiota transplant product. J Gastroenterol Hepatol, 2016; 31 (Suppl 2): 161
    20.      Paramsothy S; Kamm MA… Borody TJ. Multi donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial. Gastroenterology, 2016; 150 (1): S122-3.
    21.      Mitchell S; Jaworski A… Borody TJ. Lyophilized fecal transplantation and cryoprotectants for viable bacteria preservation. Gastroenterology, 2016; 150(4 Suppl 1): S542-3.
    22.      Aroniadis OC, Brandt LJ, Greenberg A, Borody T, et al. Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience. J Clin Gastroenterol, 2016; 50(5):398-402. doi: 10.1097/MCG.0000000000000374.
    23.      Agrawal M, Aroniadis OC, Brandt LJ… Borody TJ et al. The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J Clin Gastroenterol, 2016; 50(5):403-7.
    24.      Paramsothy S; Kamm MA… Borody TJ. Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial. Inflamm Bowel Dis, 2016; 10 (Suppl 1): S1.
    25.      Paramsothy S; Borody TJ, et al. Multi donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial and microbiota analysis. J Gastroenterol Hepatol, 2016; 31 (2): 127/155
    26.      Paramsothy S; Borody TJ, et al. FMT in ulcerative colitis is associated with specific bacterial changes-stool & colonic mucosa 16s microbiota analysis from the randomised controlled focus study. J Gastroenterol Hepatol, 2016; 31 (2): 121/126
    27.      Borody TJ; Leis S; Gadalla S; Dawson V; Jaworski A. Treatment of First-time Clostridium difficile Infection with Fecal Microbiota Transplantation. The American Journal of Gastroenterology, 2015; 110: S-1354.
    28.      Aitken J; Agrawal G…; Borody TJ, et al. Demonstration of Intracellular Mycobacterium Species In Crohn’s Disease Using Novel Technologies. The American Journal of Gastroenterology 2015; 110:S1 S-843.
    29.      Borody TJ; Grippi D; Le Busque A; Jaworski A, et al. Comparison of Eradication Protocols For Dientamoeba fragilis. The American Journal of Gastroenterology, 2015; 110: S588-9.
    30.      Borody TJ ; Grippi D; Le Busque A; Gadalla S, et al. Improved Eradication Protocol For Blastocystis hominis. The American Journal of Gastroenterology, 2015; 110: S590.
    31.      Paramsothy S; Borody TJ, et al. Donor Recruitment for Fecal Microbiota Transplantation. Inflamm Bowel Dis, 2015; 21 (7): 1600-6.
    32.      Paramsothy S; Borody TJ, et al. Gastroenterologist Perceptions of Faecal Microbiota Transplantation. World J Gastroenterol, 2015; 21 (38): 10907-14.
    33.      Borody TJ; Connelly N; Mitchell SW. Fecal Microbiota Transplantation in Gastrointestinal Diseases – What Practicing Physicians Should Know. Pol Arch Med Wewn, 2015; 125 (11): 852- 8.
    34.      Agrawal G; Borody TJ, et al. Combining Infliximab, Anti-MAP and Hyperbaric Oxygen Therapy for Resistant Fistulizing Crohn’s Disease. Future Science OA, 2015; 1:FS077.
    35.      Lin E; Borody TJ, et al. Twelve-Week Storage Trial of Microbial Viability In Lyophilized And Frozen Fecal Microbiota Preparations. Gastroenterology, 2015; 148: S-962.
    36.      Borody TJ; Peattie D; Mitchell S. Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond. Antibiotics, 2015; 4: 254-66.
    37.      Borody T, Fischer M, Mitchell S, Campbell J. Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. (Review) Expert Review of Gastroenterology and Hepatology, 2015; 9 (11): 1379-91.
    38.      Leis S; Borody TJ, et al. Fecal microbiota transplantation: A ‘How-To’ guide for nurses. Collegian, 2015; 22: 445-51.
    39.      Borody TJ; Leis S, et al. Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. UpToDate, Feb 2015.
    40.      Borody TJ; Finlayson S. Fecal microbiota transplantation for Clostridium difficile infection: a surgeon’s perspective. Semin Colon Rectal Surg, 2014; 25: 163-6.
    41.      Borody TJ; Finlayson S; Paramsothy S. Is Crohn’s disease ready for fecal microbiota transplantation? J Clin Gastroenterol, 2014; 48: 582-3.
    42.      Kelly C; Ihunnah C; Fischer M… Borody TJ, et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. The American Journal of Gastroenterology, 2014; 109: 1065-71.
    43.      Agrawal M; Aroniadis OC; Brandt LJ; Borody TJ, et al. A long-term follow-up study of the efficacy and safety of fecal microbiota transplant (FMT) for recurrent/severe/ complicated C. difficile infection (CDI) in the elderly. Gastroenterology, 2014; 146(5) (Suppl 1): S42-3.
    44.      Agrawal G; Borody TJ; Chamberlin W. ‘Global warming’ to Mycobacterium avium subspecies paratuberculosis. Future Microbiol, 2014; 9 (7): 829-32.
    45.      Borody TJ; Peattie D; Kapur A. Could fecal microbiota transplantation cure all Clostridium difficile infections? Future Microbiol, 2014; 9: 1-3.
    46.      Borody TJ; Brandt LJ; Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol, 2014; 30: 97-105.
    47.      Smits LP; Bouter KE; de Vos W; Borody TJ, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology, 2013; 145: 946-53.
    48.      Borody TJ, Peattie D, Campbell J. Therapeutic Potential of the Human Gastrointestinal Microbiome. Drug Development Research, 2013; 74(6): 385-92.
    49.      Ihunnah C; Khoruts A; Fischer M… Borody TJ, et al. Fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients. The American Journal of Gastroenterology, 2013; 108 (Suppl 1): S179-80.
    50.      Borody TJ; Finlayson S; Nowak A, et al. Anti-MAP therapy for pediatric Crohn’s disease. The American Journal of Gastroenterology, 2013; 108 (Suppl 1): S516.
    51.      Brandt L; Aroniadis O; Greenberg A… Borody TJ, et al. Safety of fecal microbiota transplantation (FMT) in immunocompromised (IC) patients with inflammatory bowel disease (IBD). The American Journal of Gastroenterology, 2013; 108 (Suppl 1): S556.
    52.      Borody TJ; Wettstein A; Nowak A, et al. Fecal microbiota transplantation (FMT) eradicates Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). 21st United European Gastroenterology Week 2013, Session Beneficial and detrimental effects of bacteria in the GI tract, October 15 2013.
    53.      Aroniadis OC; Brandt LJ; Greenberg A; Borody TJ , et al. Long-Term Follow-up Study of Fecal Microbiota Transplantation (FMT) for Severe or Complicated Clostridium difficile Infection (CDI). Gastroenterology, 2013; 144 (Suppl 1): S185.
    54.      Borody TJ; Paramsothy S; Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep, 2013; 15: 337-44.
    55.      Borody TJ ; Wettstein AR; Benstock S, et al. Superior diagnosis of H.pylori infection by 14C-urea HeliCapTM capsules versus standard PyTest® capsules. Gastroenterology, 2013; 144 (Suppl 1): S214.
    56.      Borody TJ; Brandt LJ; Paramsothy S, et al. Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile. Expert Rev Anti Infect Ther, 2013; 11: 447-9.
    57.      Borody TJ; Nowak A; Finlayson S. The GI Microbiome and its Role in Chronic Fatigue Syndrome: a Summary of Bacteriotherapy. ACNEM Journal, 2013; 31:3-8.
    58.      Borody TJ; Campbell J. Fecal Microbiota Transplantation Techniques, Applications, Issues. Gastroenterol Clin North Am, 2012; 41: 781-803.
    59.      Borody TJ; Wettstein AR; Finlayson S, et al. Diagnostic value of Fundic Red Spots in Helicobacter pylori. The American Journal of Gastroenterology, 2012; 107 (S1): A139.
    60.      Borody TJ; Nowak A; Torres M, et al. Bacteriotherapy in Chronic Fatigue Syndrome (CFS): A retrospective review. The American Journal of Gastroenterology, 2012; 107 (S1): A1481.
    61.      Borody TJ; Agrawal G; Campbell J, et al. Rescue H. pylori therapy in the clinical setting. The American Journal of Gastroenterology, 2012; 107 (S1): A1486.
    62.      Borody TJ; Wettstein A; Campbell J, et al. Fecal Microbiota Transplantation in Ulcerative Colitis: review of 24 years’ experience. The American Journal of Gastroenterology, 2012; 107 (Supp 1): A1644.
    63.      Borody TJ; Wettstein A; Leis S, et al. Resistant fistulising Crohn’s Disease treated with combination of infliximab, Anti-Map and Hyperbaric Oxygen (HBO). The American Journal of Gastroenterology, 2012; 107 (Supp 1): A1655.
    64.      Borody TJ; Wettstein AR; Benstock S, et al. Single transcolonoscopic infusion of three anti- protozoal agents for difficult Blastocystis hominis infections. Gut, 2012; 61 (Suppl 3): A292.
    65.      Gitlin L; Borody TJ; Chamberlin W, et al. Mycobacterium avium ss paratuberculosis-associated diseases: piecing the Crohn’s puzzle together. J Clin Gastroenterol, 2012; 46 (8): 649–55.
    66.      Campbell J; Borody TJ; Leis S. The many faces of Crohn’s Disease: Latest concepts in etiology. Open Journal of Internal Medicine, 2012; 2 (2): 107-15.
    67.      Borody TJ; Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol, 2011; 9 (2): 88-96.
    68.      Bakken JS; Borody TJ ; Brandt LJ, et al. Fecal microbiota transplantation Workgroup, Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol and Hepatol, 2011; 9: 1044–9.
    69.      Borody TJ; Torres, M; Campbell, J, et al. Reversal of inflammatory Bowel disease (IBD) with recurrent Faecal Microbiota Transplants (FMT). The American Journal of Gastroenterology, 2011; 106 (S2): S366.
    70.      Borody TJ; Campbell JL; Torres M, et al. Reversal of Idiopathic Thrombocytopenic Purpura (ITP) with fecal microbiota transplantation (FMT). The American Journal of Gastroenterology, 2011; 106 (S2): S352.
    71.      Chamberlin W; Borody TJ; Campbell J. Primary treatment of Crohn’s disease combined antibiotics taking centre stage. Expert Rev Clin Immunol, 2011; 7 (6), 751–60.
    72.      Borody TJ; Wettstein A; Campbell J, et al. Intra-colonic infusion of anti-parasite agents for resistant Blastocystis hominis Long-term follow up. The American Journal of Gastroenterology, 2011; 106 (S2): S165.
    73.      Borody TJ; Leis SM; Campbell J, et al. Fecal microbiota transplantation (FMT) in Multiple Sclerosis (MS). The American Journal of Gastroenterology, 2011; 106 (S2): S352.
    74.      Borody TJ; Rosen DM; Torres M, et al. Myoclonus-dystonia affected by GI Microbiota. The American Journal of Gastroenterology, 2011; 106 (S2): S352.
    75.      Borody TJ; Campbell J. Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepatol, 2011; 5 (6): 653–5.
    76.      Bakken JS; Borody TJ; Brandt LJ, et al. (Fecal microbiota transplantation Workgroup), Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol and Hep, 2011; 9 (12): 1044-9.
    77.      Brandt LJ; Borody TJ; Campbell J. Endoscopic Fecal Microbiota Transplantation ‘‘First-Line’’ Treatment for Severe Clostridium difficile Infection? J Clin Gastroenterol, 2011; 45 (8): 655-7.
    78.      Chamberlin W; Borody TJ; Campbell J. Primary treatment of Crohn’s disease combined antibiotics taking centre stage. Expert Rev Clin Immunol, 2011; 7 (6): 751–60.
    79.      Grehan MJ; Borody TJ; Leis S, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol, 2010; 44: 551-61.
    80.      Wettstein A; Borody TJ; Wee T, et al. Novel intra-colonic infusion of three anti-parasite agents for resistant Blastocystis hominis infections. Gut, 2009; 58 (Suppl II): A113.
    81.      Borody TJ; Campbell J; Torres M, et al. Changes in Crohn’s Disease activity index and C- reactive protein levels during anti-MAP therapy. The American Journal of Gastroenterology, 2009; 104 (S3): S482-3.
    82.      Borody TJ; Campbell J; Torres M, et al. Entamoeba Histolytica: Another cause of Crohn’s Disease. The American Journal of Gastroenterology, 2009; 104 (S3): S364.
    83.      Borody TJ; Torres M; Campbell J et al. Treatment of severe constipation improves Parkinson’s Disease (PD) symptoms, The American Journal of Gastroenterology, 2009; 104 (S3): S367.
    84.      Borody TJ. Is the Infected Patient too ‘Difficile’ to Treat? The Australian Society for Microbiology. Perth 2009 SY03.1
    85.      Borody TJ; Ketheeswaran S; Leis S. Anti-MAP Rescues anti-TNF Failures for over 4 years. Gastroenterology, 2009; 136 (5) Suppl 1: A-681.
    86.      Borody TJ; Torres M; Hills L. Colchicine plus Olsalazine for Treatment of Constipation- Predominant Irritable Bowel Syndrome. Gastroenterology, 2009; 136 (5) Suppl 1: A-484.
    87.      Borody TJ; Leis S; Torres M. Years continuous Anti-MAP Therapy for Crohn’s – Observation of Side Effects. The American Journal of Gastroenterology, 2008; 103 (S1): S454-5.
    88.      Foell D; Wittkowski H; Borody TJ, et al. Phagocyte-Specific SI00 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol, 2008; 216: 183-92.
    89.      Borody TJ; Wettstein AR; Leis S, et al. Clostridium difficile complicating Inflammatory Bowel Disease: Pre- and post-treatment findings. Gastroenterology 2008; 104 (4) Suppl 1: A-361.
    90.      Borody TJ; Wettstein AR; Campbell J, et al. Rapid and superior diagnosis of H. Pylori infection by 14C-urea Heliprobe™ test versus the PYtest®. Gastroenterology 2008; 104 (4) Suppl 1: A-329.
    91.      Ramrakha S; Borody TJ; Herdman KJ, et al. Nasal Vs Oro-Nasal Oxygenation and Capnography During Endoscopy N. Gastrointest Endosc, 2008; 67(5): AB283.
    92.      Foell D; Ren Z; Wittkowski H; Daebritz J; Roth,J; Borody TJ ; Clancy R. Mucosal release of phagocyte-specific S100 proteins is strongly enhanced during active inflammatory bowel disease. J Pathol, 2008; 216 (2): 183-92.
    93.      Ren Z; Turton, J; Borody TJ , et al. Selective Th2 pattern of cytokine secretion in Mycobacterium avium subsp. Paratuberculosis infected Crohn’s disease. J Gastroenterol Hepatol, 2008; 23 (2): 310-4.
    94.      Borody TJ ; Wettstein AR; Leis S; Torres M. Use of Combination therapy as first line and salvage therapy in parasite infection. Gut, 2007; 56 (suppl III): A303.
    95.      Chamberlain W; Borody TJ; Naser S. MAP-associated Crohn’s Disease, MAP, Koch’s postulates, causality and Crohn’s Disease.Dig Liver Dis, 2007; 39(8):790-4.
    96.      Borody TJ. Bilkey S. Wettstein AR. Leis S. Pang G. Tye S. Anti-mycobacterial therapy in Crohn’s disease heals mucosa with longitudinal scars. Dig Liver Dis, 2007; 39 (5): 438-44.
    97.      Borody TJ; Heifets LB. Severe recurrent Crohn’s Disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial therapy). Gut, 2006; 55: 1211.
    98.      Borody TJ; PSK. A Protein-Bound Polysaccharide from Coriolus Versicolor, In Combination With Standard Treatments Extends Overall Survival and Disease-Free Survival In Cancer Patients. Intern Med J, 2006; 36 (Suppl. 4): A141-62.
    99.      Ramrakha SR; Borody TJ; Wettstein A, et al. Investigating the tolerability of four bowel preparations – the taste test. J Gastroenterol Hepatol, 2006; 21 (Suppl 4): A286-99.
    100.   Borody TJ; Bilkey S; Wettstein AR, et al. Anti-Mycobacterium avium SS Paratuberculosis (MAP) Therapy and fistula closure in patients with Severe Crohn’s Disease. The American Journal of Gastroenterology, 2006; A101: S440.
    101.   Borody TJ; Pang G; Wettstein AR, et al. Efficacy and safety of rifabutin-containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther, 2006; 23: 481-8.
    102.   Borody TJ; Clancy R; Pang G. Australian Anti-map trials. Microbial-host interactions workshop. 2006
    103.   Borody TJ; Ramrakha S; Pang G, et al. Effects of supplemental oxygen during endoscopy. J Gastroenterol Hepatol, 2005; 20 (Suppl): A49.
    104.   Ren Z; Borody TJ; Pang G, et al. Selective reduction of anti-Helicobacter pylori IgG subclass antibody in gastric carcinoma. J Gastroenterol Hepatol, 2005; 20: 1338-43.
    105.   Henriksson A; Borody TJ; Clancy R Probiotics under the regulatory microscope. Expert Opin Drug Saf, 2005; 4 (6): 1135-43.
    106.   Borody TJ; Clancy R; Wettstein AR, et al. Anti-MAP therapy in the treatment of active Crohn’s disease. J Gastroenterol Hepatol, 2005; 20: A2.
    107.   Borody TJ; Clancy R; Wettstein A, et al. Anti-MAP therapy induces and maintains remission in severe Crohn’s disease. Ann NY Acad Sci 2005 Münster Germany, 2-3
    108.   Borody TJ; Ren Z; Pang G, et al. Evaluation of anti-Helicobacter pylori IgG2 antibody for the diagnosis of Helicobacter pylori infection in western and Chinese populations. Aliment Pharmacol Ther, 2005; 21: 83-9.
    109.   Borody TJ. How effective are quadruple therapies as first-line H. pylori eradication therapies? Nat Rev Gastroenterol Hepatol, 2005; 2: 174-5.
    110.   Borody TJ ; Leis S; Chongman J, et al. Novel appearance of healing mucosa following antimycobacterium avium paratuberculosis for Crohn’s disease. J Gastroenterol Hepatol, 2004; 19: A210.
    111.   Borody TJ; Herdman KJ; Wettstein A, et al. Use of hyperlac in Coeliac disease and its effect on disaccharidase deficiency. J Gastroenterol Hepatol, 2004; 19: A222.
    112.   Borody TJ; Wettstein AR; Herdman KJ, et al. Dientamoeba fragilis (Df) and Irritable Bowel Syndrome (IBS). 2004 ASM Sydney National Conference p17
    113.   Borody TJ; Warren EF; Leis SM, et al. Bacteriotherpay using fecal flora: toying with human motions. J Clin Gastroenterol, 2004; 38 (6): 475-83.
    114.   Clancy R; Borody TJ; Ren Z; Pang G. Can the response to eradication therapy in Helicobacter pylori infection be predicted? J Gastroenterol, 2004; 17 (Suppl B): 58B-61B.
    115.   O’Morain C; Borody TJ; Farley A. et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther, 2003; 17 (3): 415-20.
    116.   Borody TJ; Ashman O. Lactoferrin: milking ulcers? Digest Liver Dis, 2003; 35: 691-3.
    117.   Borody TJ; Leis SM; Chongnan J, et al. Faecal bacteriotherapy (FB) for chronic C. difficile syndromes. J Gastroenterol Hepatol, 2003; 18: B8.
    118.   Borody TJ; Warren EF; Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol, 2003; 37 (1): 42-7.
    119.   Borody TJ; Ren Z; Pang G; Clancy R Impaired host immunity contributes to Helicobacter pylori eradication failure. The American Journal of Gastroenterology, 2002; 97 (12): 3032-7.
    120.   Borody TJ; Robertson C; Wettstein A, et al. Irritable bowel syndrome and Dientamoeba fragilis. IBIS News and Views, 2002; 4-5.
    121.   Borody TJ; Clancy R; Warren EF, et al. Varying gastric sensitivities of H. Pylori. J Gastroenterol Hepatol, 2002; 17 (Suppl): A102.
    122.   Borody TJ; Warren,EF; Wettstein A, et al. Eradication of Dientamoeba fragilis can resolve IBS- like symptoms. J Gastroenterol Hepatol, 2002; 17 (Suppl): A103.
    123.   Borody TJ; Warren EF; Recabarren P, et al. Rifabutin – key to H. pylori rescue therapy? J Gastroenterology Hepatol, 2002; 17 (Suppl): A102.
    124.   Borody TJ; Leis S; Warren EF; Surace R. Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Digest Liver Dis, 2002; 34 (1): 29-38.
    125.   Baladas HG; Borody TJ; Smith GS et al. Laparoscopic excision of a Brunner’s gland hamartoma of the duodenum. Surg Endosc, 2002; 16: 1636.
    126.   Sintchenko V; Veroerd,P; Mitchell H; Sacco J; Borody TJ  Direct antibiotic susceptibility testing of Helicobacter pylori: does it have a role? J Gastroenterol Hepatol, 2001; 16: A35.
    127.   Borody TJ; Leis S; McGrath K, et al. Treatment of chronic constipation and colitis using human probiotic infusions. In: Proceedings of Prebiotics and Probiotics and the New Foods Conference, Rome, 2001; 2-4: 228.
    128.   Borody TJ.  Letter to the Editor – Response to Drs Famularo et al. The American Journal of Gastroenterology, 2001; 96 (7) 2262-4.
    129.   Wettstein A; Borody TJ; Warren E. Skewered diverticulum: another cause of abdominal pain. Internal Med J, 2001; 31 (8): 495-6.
    130.   Ren Z; Pang G; Clancy R; Li LC; Soon-Lee C; Batey R; Borody TJ ; Dunkley M. Shift of the gastric T-Cell response in gastric carcinoma. J Gastroenterol Hepatol, 2001; 16 (2): 142-8.
    131.   Borody TJ. Response to “Fecal bacteriotherapy or probiotics for the treatment of intestinal diseases?” The American Journal of Gastroenterology, 2001; 96: 2262-3.
    132.   Mitchell HM; Brusentsev S; Hazell SL; Borody TJ, et al. A high level of primary resistance to metronidazole and clarithromycin in previously untreated symptomatic patients presenting for endoscopy in Australia. Gut, 2000; 47: A107.
    133.   Borody TJ. Flora power – fecal bacteria cure chronic C. difficile diarrhoea (editorial). The American Journal of Gastroenterology, 2000; 95 (11): 3028-9.
    134.   Borody TJ; Leis S; Surace R, et al. Treatment of severe Crohn’s disease using rifabutin- macrolide-clofazimine combination – results at 38-43 months. J Gastroenterol Hepatol, 2000; 15: J102.
    135.   Borody TJ; Leis S; Surace R; Goodger J. Treatment of severe Crohn’s disease (CD) using rifabutin-macrolide-clofazimine combination: results at 30-37 months. Gastroenterology, 2000; 118: A1334.
    136.   Borody TJ. Helicobacter pylori pandemic – The Evolving Concepts 2000
    137.   De Boer WA; Borody TJ. Treatment failures and secondary resistance to antibiotics. A growing concern in Helicobacter pylori therapy. Digest Liver Dis, 2000; 32: 673-5.
    138.   Ren Z; Pang G; Lee R; Batey R; Dunkley M; Borody TJ ; Clancy R. Circulating T-cell response to H. pylori infection in chronic gastritis. Helicobacter, 2000; 5 (3): 135-41.
    139.   Lignell A; Surace R; Bottiger P; Borody TJ. Symptom improvement in Helicobacter pylori-positive non-ulcer dyspeptic patients after treatment with the carotenoid Astaxanthin. Abstract, 12th International Carotenoid Symposium, Cairns, Australia 1999
    140.   Borody TJ; Carsula S; O’Shea J, et al. Macroscopic colitis – a separate entity? J Gastroenterol Hepatol, 1999; 14: A172.
    141.   Talley NJ; Chang FY; Wyatt JMA; Adams S; Lau A; Borody T; Chen TS; Daskolopolos G; Cheung K; Talley NA. Erratum: Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 1999; 13(6): 841.
    142.   Borody TJ. Helicobacter pylori eradication failure – “Salvage” therapies needed. Ital J. Gastroenterol Hepatol, 1998; 30 (4): 375-7.
    143.   Borody TJ; Pearce,L; Bampton PA, et al. Modified Clarithromycin – Quad Therapy as “Salvage” treatment for H. pylori eradication failure (EF). J Gastroenterol Hepatol, 1998; 13 (Suppl): A174.
    144.   Borody TJ; Pearce L; Bampton PA, et al. In vitro Helicobacter pylori resistance to metronidazole and clarithromycin in an Australian population. J Gastroenterol Hepatol, 1998; 13 (Suppl): A157.
    145.   Borody TJ; Shortis NP; Reyes E. Eradication Therapies for Helicobacter pylori.  J  Gastroenterol, 1998; 33 (Suppl): 53-6.
    146.   Borody TJ; Pearce L; Bampton PA, et al. Eradication of H. pylori using pantoprazole quad therapy in routine consultants practice. J Gastroenterol Hepatol, 1998; 13 (Suppl): A140.
    147.   Talley NJ; Chang FY; Wyatt,JM; Adams S; Lau A; Borody TJ , et al. Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther, 1998; 12: 527-32.
    148.   Borody TJ; Pearce L; Bampton PA; Leis S. Treatment of severe Crohn’s disease (CD) using rifabutin-macrolide-clofazimine combination: interim report. Gastroenterology, 1998; 114: A938.
    149.   De Boer WA; Borody TJ. Towards monotherapy for Helicobacter pylori infection: first result with a single triple capsule. Gastroenterology, 1998; 114 (Suppl): A98.
    150.   Bampton PA; Shortis N; Pearce L; Borody TJ. A cost analysis of different “test and treat” strategies for the management of patients on maintenance therapy for peptic ulcer disease. J Gastroenterol Hepatol, 1997; 12 (Suppl): A246.
    151.   Pearce L; Bampton P; Borody TJ; Shortis NP. Modification of the colonic microflora using probiotics – The way forward? Gut, 1997; 41: A63.
    152.   Pearce LM; Shortis NP; Leis SM; Borody TJ. The use of probiotic therapy as a novel approach to the management of irritable bowel syndrome: a preliminary study. J Gastroenterol Hepatol, 1997; 12 (Suppl): A129.
    153.   Borody TJ; Bampton P; Moont M et al. Letter Re: W de Boer: Gastric outlet obstruction and Helicobacter pylori. The American Journal of Gastroenterology, 1997; 92(9):1576-7.
    154.   Borody TJ. Gastro-oesophageal reflux disease. Clinical Concepts, 1997; 2-4.
    155.   Borody TJ. What is the optimal therapy for Helicobacter pylori eradication? In: OESO – The Esophagogastric Junction. John Libbey (ed), Eurotext. Paris, 1996; 653-6.
    156.   Borody TJ; Pearce L; Shortis NP et al. Occult H. pylori infection: detection and treatment. Gastroenterology, 1996; 110 (Suppl): A68.
    157.   Borody TJ; Shortis NP; Chongnan J, et al. Eradication failure (EF) after H. pylori treatment – further therapies. Gastroenterology, 1996; 110 (Suppl): A67.
    158.   Borody TJ; Andrews P; Shortis NP, et al. Eradicating H. pylori – are we winning the battle? In: Proceedings of Helicobacter pylori and Gastric Cancer: State of the Art, 1996 Ulm Germany 23-24.
    159.   De Boer WA; Thys JC; Borody TJ et al. Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens. Eur J Gastroenterol Hepatol, 1996; 8 (7): 641-3.
    160.   Borody TJ. What is the optimal therapy for Helicobacter pylori eradication? Ross Gastroenterol Zh, 1996; 3: 42-6. (article in Russian)
    161.   Borody TJ; Pearce L; Shortis N; Chongnan J. From Intestinal Metaplasia to Gastric Cancer – Whither surveillance? Helicobacter pylori and Gastric Cancer – State of the Art Congress, 1996; Ulm Germany, 23-24.
    162.   Borody TJ; Andrews P; Shortis N. Evaluation of Whole Blood Antibody Kit to Detect Active Helicobacter pylori Infection. The American Journal of Gastroenterology, 1996; 91 (12): 2509-12.
    163.   Borody TJ. Bacteriotherapy for Chronic Fatigue Syndrome – A long-term follow-up study. Proceedings of ACMA Complementary Medicine Sydney 1995.
    164.   Borody TJ; Andrews P; Fracchia G, et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut, 1995; 37 (4): 477-81.
    165.   Borody TJ. Dyspepsia, Current Therapeutics, 1995; 24-5.
    166.   Andrews P; Borody TJ; Shortis N; Thompson S. Bacteriotherapy for Chronic Constipation – A long-term follow-up. Gastroenterology, 1995; 108: A563.
    167.   Borody TJ; Andrews P; Shortis NP; Hyland L. 7 Day Therapy for   Helicobacter pylori. Gastroenterology, 1995; 108: A62.
    168.   Borody TJ; Clark IW; Andrews P, et al. Eradication of Helicobacter pylori may not reverse severe gastric dysplasia. The American Journal of Gastroenterology, 1995; 90(3): 498-9.
    169.   Borody TJ. Methods of Oxygen Delivery during Upper Gastrointestinal Endoscopy. Endoscopy, 1995; 26(3): 320-1.
    170.   Borody TJ. Helicobacter infection – The current state of play. Curr Ther, 1994; 1:9-12.
    171.   Borody TJ; Andrews P; Mancuso N, et al. Helicobacter pylori reinfection rate, in patients with cured duodenal ulcer. The American Journal of Gastroenterology, 1994; 89(4): 529-32.
    172.   Borody TJ; Andrews P; Shortis NP, et al. Non-ulcer Dyspepsia sub-groups and therapy for Helicobacter pylori. The American Journal of Gastroenterology, 1994; 89: 1365.
    173.   Borody TJ; Andrews P; Shortis NP. Features of patients who fail all attempts at Helicobacter pylori (HP) eradication. The American Journal of Gastroenterology, 1994; 89: 1365.
    174.   Borody TJ; Andrews P Shortis NP, et al. Failure to use combined tests may miss Helicobacter pylori (HP) diagnosis. The American Journal of Gastroenterology, 1994; 89 (8): 1348.
    175.   Andrews P; Borody TJ; Shortis NP, et al. Chronic Constipation (CC) may be reversed by “Bacteriotherapy”. Gastroenterology, 1994; 106: A459.
    176.   Borody TJ; Andrews P; Shortis NP, et al. Intestinal Metaplasia (IM) – Occurrence in Korean vs Matched Australian Patients with H. pylori Gastritis. Gastroenterology, 1994; 106: A56.
    177.   Borody TJ; Andrews P; Shortis NP, et al. Optimal H. pylori (HP) Therapy – A Combination of Omeprazole and Triple Therapy (TT). Gastroenterology, 1994; 106: A55.
    178.   Borody TJ; Andrews P; Shortis NP, et al. Eradication of H. pylori in Dyspeptic Patients with Prior DU Surgery. Gastroenterology, 1994; 106: A55.
    179.   Borody TJ; Brandl S; Andrews P, et al. Use of High Efficacy, Lower Dose Triple Therapy to Reduce Side Effects of Eradicating Helicobacter pylori. The American Journal of Gastroenterology, 1994; 89 (1): 33-8.
    180.   Andrews P; Borody TJ. “Putting back the bugs”: bacterial treatment relieves chronic constipation and symptoms of Irritable Bowel Syndrome. Med J Aust, 1993; 159: 633-4.
    181.   Borody TJ; Andrews P; Jankiewicz E, et al. Apparent reversal of early gastric mucosal atrophy after Triple Therapy for Helicobacter pylori. The American Journal of Gastroenterology, 1993; 88(8): 1266-8.
    182.   Brandl S; Borody TJ; Andrews P, et al. Supplemental oxygen therapy during endoscopy and recovery (Letter), Gastrointest Endosc, 1993; 39: 209.
    183.   Borody TJ; Andrews P; Brandl S; Carroll M. H. pylori (HP) eradication side effects, compliance : 14 day vs 12 day Triple therapy (TT). Gastroenterology, 1993; 104: A44.
    184.   Borody TJ; Andrews P; Brandl S, et al. Does H. pylori (HP) play a role in esophageal reflux? Gastroenterology, 1993; 104: A44.
    185.   Borody TJ; Andrews P; Brandl S; Devine M. Relevance of in-vitro metronidazole resistance to H. pylori (HP) eradication and eradication failure. Gastroenterology, 1993; 104: A44.
    186.   Borody TJ. Laparoscopic vagotomy for chronic duodenal ulcer (Letter to the Editor). Med J Aust, 1992; 156 (2): 140.
    187.   Borody TJ; Andrews P; Mancuso N, et al. Helicobacter pylori reinfection 4 years post- eradication, The Lancet, 1992; 339 (8804): 1295.
    188.   Mancuso N; Borody TJ; Ostapowicz N, et al. Frequent early extracorporeal shock wave lithotripsy and simvastatin accelerate gallbladder fragment clearance. Gastroenterology, 1992; 102: A321.
    189.   Borody TJ; Brandl S; Andrews P, et al. High Efficacy, Low dose triple therapy (TT) for Helicobacter pylori (HP). Gastroenterology, 1992; 102 (4): A44.
    190.   Borody TJ; Brandl S; Andrews P et al. H. pylori eradication Failure (EF) – Further treatment possibilities. Gastroenterology, 1992; 102: A43.
    191.   Andrews PJ; Barnes P; Borody TJ. Chronic constipation reversed by restoration of bowel flora. A case and hypothesis. Eur J Gastroenterol Hepatol, 1992; 4:245-7.
    192.   Borody TJ; Brandl S; Andrews P, et al. Helicobacter pylori-negative gastric ulcer. The American Journal of Gastroenterology, 1992; 87 (10): 1403-6.
    193.   Borody TJ; George, LL; Brandl S, et al. Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. The American Journal of Gastroenterology, 1992; 87 (10): 1390.
    194.   Axon ATR; Borody TJ; Dixon M, et al. Panel Discussion: Short-term and long-term consequences of gastritis and duodenitis. Eur J Gastroenterol Hepatol, 1992; 4 (Suppl 2): S53- 64.
    195.   Borody TJ. Possibilities for Helicobacter pylori suppression/eradication. Eur J Gastroenterol Hepatol, 1992; 4 (Suppl 2): S37-40.
    196.   Borody TJ; George LL; Brandl S, et al. Helicobacter pylori eradication with doxycycline: metronidazole: bismuth subcitrate triple therapy. Scand J Gastroenterol, 1992; 27 (4): 281-4.
    197.   Brandl S; Borody TJ; Andrews P, et al. Oxygenating mouthgard alleviates hypoxia during gastroscopy. Gastrointest Endosc, 1992; 38 (4): 415-7.
    198.   Borody TJ; Brandl S; Andrews P. Adverse Effects of Triple Therapy, 17th International Congress of Chemotherapy (Proceedings), Berlin Futuramed-Ver-Ges Munchen 1991.
    199.   Borody TJ; Brandl S; Andrews P, et al. Use of 5-amino salicylic acid in irritable bowel syndrome. Gastroenterology, 1991; 102: A428.
    200.   Borody TJ; George LL; Brandl S, et al.  Helicobacter Pylori-Negative   Duodenal Ulcer. The American Journal of Gastroenterology, 1991; 86 (9): 1154-7.
    201.   Borody TJ; Andrews P; Brandl S, et al. Endoscopic diagnosis of Helicobacter pylori (HP) – Approaching the “gold standard”. Abstracts II, World Congresses of Gastroenterology, Sydney, Australia, 1990; PD91.
    202.   Rodionoff P; Hyland L; Ostapowicz N… Borody TJ. Triple Therapy for Helicobacter pylori (HP) eradication – 2 or 4 weeks? Abstracts I, World Congresses of Gastroenterology, Sydney, Australia, 1990; PP938.
    203.   Andrews P; Ostapowicz N; Lenne J… Borody TJ. Who needs maintenance H2RA’s after duodenal ulcer ‘cure’? Abstracts II, World Congress of Gastroenterology, Sydney, Australia, 1990; PD332.
    204.   Borody TJ; Lenne J; Moore-Jones D, et al. Is doxycycline more effective than tetracycline HCL in triple therapy of Helicobacter pylori? Gastroenterology, 1990; 98: A24.
    205.   Borody TJ; Byrnes D; George L; Andrews P. How common are duodenal ulcers negative for Helicobacter pylori? Gastroenterology, 1990; 98: A23.
    206.   George LL; Borody TJ; Andrews, P, et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust, 1990; 153 (3): 145-9.
    207.   Borody TJ; Cole P; Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust, 1989; 151(8): 431-5.
    208.   Borody TJ; Noonan S; Cole P, et al. L Triple Therapy for C. pylori can reverse hypochlorhydria. Gastroenterology, 1989; 96: A53.
    209.   Borody TJ; George L; Taylor R, et al. S C. pylori-related non-ulcer dyspepsia improves after C. pylori eradication. Gastroenterology, 1989; 96: A170.
    210.   Borody TJ; Noonan S; Cole P, et al. Duodenal ulcer recurrence in patients remaining C. pylori (CP)-negative long term post-eradication. Gastroenterology, 1989; 96: A52.
    211.   Borody TJ; Noonan S; Cole P, et al. Oral vancomycin can reverse idiopathic constipation. Gastroenterology, 1989; 96: A52.
    212.   Borody TJ; George, L; Andrews P, et al. Bowel flora alteration: A potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust, 1989; 150(10): 604.
    213.   Borody TJ; Carrick, J. Long-term Campylobacter pylori recurrence following apparent eradication. Gastroduodenal pathology and Campylobacter pylori, 1989; 591.
    214.   Carrick J; Daskalopoulos G; Hazell S; Lee A; Borody TJ. The role of Campylobacter pylori and gastric metaplasia in duodenal ulceration. Aust NZ J Med, 1988; 18: 191.
    215.   Mitchell HM; Lee A; Berkowicz J; Borody TJ. The use of serology to diagnose active Campylobacter pylori infection. Med J Aust, 1988; 149 (11-12): 604-9.
    216.   Borody TJ; Cole P; Noonan, S. Long-term Campylobacter pylori recurrence   post- eradication. Gastroenterology 1988; 94: A43.
    217.   Borody TJ. Double blind study of Ballobes intragastric balloon without diet or behaviour modification, International Ballobes symposium, Stockholm 1988.
    218.   Borody TJ. Complications and side effects of Ballobes intrgastric balloon in 427 patients, International Ballobes Symposium Stockholm 1988.
    219.   Borody TJ. Campylobacter, Gastritis and Ulceration, Viewpoint in Ulcer Disease. Adis Press 1987.
    220.   Borody TJ; Doust B; Carrick J. Gallstones: Optimal Diagnostic Techniques, Patient Management, 1987; 81-9.
    221.   Borody TJ. Campylobacter pyloridis in the gastrointestinal tract: Recent research and implications. Curr Ther, 1987; 25-31.
    222.   Borody TJ; Carrick J; Brandl S; Cole P. Side-effects and complications in 110 consecutive patients with Danish (Ballobes) gastric balloon. Aust NZ J Med, 1987; 17 (Supp 1): 508.
    223.   Borody TJ; Carrick J; Brandl S; Cole  P. Evaluation of the Danish Gastric Balloon in the treatment of obesity. Aust NZ J Med, 1987; 17 (Suppl 1): 508.
    224.   Borody TJ; Hennessy W; Daskalopoulos G, et al. Double blind trial of De-nol in non-ulcer dyspepsia associated with Campylobacter pyloridis gastritis. Gastroenterology, 1987; 92 (5): 1324.
    225.   Daskalopoulos G; Carrick J; Borody TJ, et al. Do Campylobacter pyloridis and gastric metaplasia have a role in duodenal ulceration? Gastroenterology, 1987; 92 (5): 1363.
    226.   Borody TJ; Daskalopoulos G; Brandl S, et al. Dyspeptic symptoms improve following eradication of gastric Campylobacter pyloridis. Gastroenterology, 1987; (5): 1324.
    227.   Daskalopoulos G; Borody TJ; Carrick J, et al. Relationship of patients’ country of origin to endoscopic frequency of Campylobacter pyloridis gastritis. Gastroenterology, 1987; 92 (5): 1363.
    228.   Borody TJ; Carrick J; Cole P. Pneumogastroplasty in the obese using the Danish (Ballobes) gastric balloon. Gastroenterology, 1987; 92 (5): 1363.
    229.   Borody TJ; Carrick J; Hazell SL. Symptoms improve following the eradication of gastric Campylobacter pyloridis. Med J Aust, 1987; 146 (8): 450-1.
    230.   Carrick J; Doust B; Coleman M, et al. Methyl tertiary butyl ether cholelitholysis of calculi in the gallbladder and bile ducts. Aust NZ J Med, 1987; 17 (4): 435-40.
    231.   Hazell SL; Hennessy WB; Borody TJ, et al. Campylobacter pyloridis gastritis II: Distribution of bacteria and associated inflammation in the gastroduodenal environment. The American Journal of Gastroenterology, 1987; 82: 297-301.
    232.   Hazell SL; Borody TJ; Gal A; Lee A. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis. The American Journal of Gastroenterology, 1987; 82 (4): 292-6.
    233.   Carrick J; Hennessy W. The incidence of C. pyloridis gastritis in healthy volunteers. Aust NZ J Med, 1987; 17 (Suppl l): 137.
    234.   Borody TJ; Brandl S; Carrick J; Hennessy W. Initial experience with pseumogastroplasty in obese patients. Aust NZ J Med 1987; 17 (Suppl 1): 136.
    235.   Kellow JE; Borody TJ; Phillips SF, et al. Sulfapyridine appearance in plasma and salicylazosulfapyridine. Another simple measure of intestinal transit, Gastroenterology, 1986; 91 (2): 396-400.
    236.   Hazell SL; Borody TJ; Gal A; Lee A. Rapid detection of Campylobacter pyloridis on the gastric mucosa and its association with gastritis. Aust NZ J Med, 1986; 16: 608.
    237.   Carrick J; Doust B; Hugh T… Borody TJ. Initial experience with methyl tertiary butyl ether cholelitholysis.  Aust NZ J Med. 1986; 16: 614.
    238.   Lee A; Carrick J; Borody TJ. Campylobacter pyloridis infection as possible complication of weight loss therapy. The Lancet, 1986; 2 (8519): 1343.
    239.   Borody TJ; Carrick J. Gallstones – What can be done and when to recommend it.  Curr Ther, 1986; 49-58.
    240.   Carrick J; Hazell S; Borody TJ; Hennessy W. Incidence of Campylobacter pyloridis gastritis in AIDS and other immunosuppressed patients. The American Journal of Gastroenterology. 1986; 81: 853.
    241.   Kellow JE; Borody TJ; Phillips SF, et al. Human interdigestive motility: Variations in patterns from oesophagus to colon. Gastroenterology, 1986; 91 (2): 386-95.
    242.   Borody TJ. Is gallstone dissolution practical? Aust NZ J Med, 1986; 16: 118.
    243.   Thistle JL; Borody TJ; Quigley EMM; Tucker RL, et al. Dissolution of cholesterol gallstones in the gallbladder and bile ducts in humans using methyl tertiary butyl ether. Klin Wochenschr, 1985; 63: 55.
    244.   Borody TJ; Quigley EM; Phillips SF, et al. Effects of morphine and atropine on motility and transit in the human ileum. Gastroenterology, 1985; 89 (3): 562-70.
    245.   Kellow J; Borody TJ; Brown M, et al. Validation of sulfapyridine appearance in blood as a measure of small bowel transit. Gastroenterology, 1985; 88: 1442.
    246.   Kellow J; Borody TJ; Brown M; Phillips S. Effects of morphine on motility and transit in human small intestine. Gastroenterology, 1985; 88: 1442.
    247.   Borody TJ; Kellow J; Haddad A; Phillips S. The migrating motor complex; distribution along the human bowel. Gastroenterology, 1985; 88: 1331.
    248.   Borody TJ; Quigley EMM; Wienbeck M; Phillips SF. Effects of morphine, atropine and naloxone on the human ileocaecal sphincter. Aust NZ J Med, 1985; 15 (Suppl 1): 175.
    249.   Allen MJ; Borody TJ; Bugliosi TF, et al. Rapid dissolution of gallstones by methyl tert-butyl ether. New Engl J Med, 1985; 312 (4): 217-20.
    250.   Allen MJ; Borody TJ; Thistle JL. In-vitro dissolution of cholesterol gallstones. A study of factors influencing rate and a comparison of solvents. Gastroenterology, 1985; 89(5):1097-103.
    251.   Stryker SJ; Borody TJ; Phillips SF, et al. Motility of the small intestine after proctocolectomy and ileal pouch-anal anastomosis. Ann Surg, 1985; 201(3): 351-6.
    252.   Allen MJ; Borody TJ; Bugliosi TF, et al.  Cholelitholysis using methyl tertiary butyl ether. Gastroenterology. 1985; 88(1 pt 1): 122-5.
    253.   Wienbeck M; Phillips SF; Quigley EMM; Borody TJ; Tucker RL. Motilitat am ileokolisohen ubergang des Menschen. Verh Dtsch Gas Inn. Med, 1984; 90:543-4.
    254.   Wienbeck M; Phillips SF; Borody TJ, et al. Antidiarrhoeische mechanism in ileum, opiat und anticholinergika – wirkungen. Verh dtsch Gas Inn. Med, 1984; 90: 543-4.
    255.   Quigley EMM; Borody TJ; Wienbeck M; Phillips SF. Effects of morphine on intestinal motility and transit – Studies in distal ileum and ileocolonic junction of a healthy man. Irish J Med Sci, 1985; 154 (1): 49-50.
    256.   Stryker SJ; Borody TJ; Kelly KA; Phillips SF. Small intestinal motor patterns from Ileoanal anastomosis. Digest Dis Sci, 1984; 29:548.
    257.   Quigley EM; Borody TJ; Phillips SF, et al. Motility of the terminal ileum and ileocecal canal sphincter in healthy humans. Gastroenterology, 1984; 87(4): 857-6.
    258.   Bugliosi TF; Allen MJ; Borody TJ, et al. Rapid gallstone dissolution in dogs using MTBE and the aspiration-infusion pump. Gastroenterology, 1984; 86: 1350.
    259.   Borody TJ; Byrnes DJ; Henderson L. Molecular forms of CCK in human postprandial plasma. Gastroenterology, 1984; 86: 1032.
    260.   Borody TJ; Quigley EEM; Wienbeck M, et al. Migrating motor complexes fade out in the human terminal ileum. Clin Res, 1984; 32: 34A.
    261.   Borody TJ; Byrnes D; Bell D; Henderson L. The migrating motor complex – its relation to circulating CCK, motilin and pancreatic polypeptide in irritable bowel patients and in controls. Clin Res, 1984; 32: 23A.
    262.   Borody TJ; Byrnes DJ; Titchen DA. Motilin and migrating myoeletric complexes in the pig and the dog. Quart J Exp Physiol, 1984; 69: 875-90.
    263.   Allen MJ; Borody TJ; La Russo NF; Thistle JL. Gallstone dissolution a comparison of solvents for direct biliary perfusion. Hepatology, 1983; 3: 809.
    264.   Allen MJ; May GR; Borody TJ, et al. Methyl tertiary butyl either rapidly dissolves gallstones in vitro and in vivo. Hepatology, 1983; 3: 809.
    265.   Borody TJ; Daskalopoulos G; Best SP, et al. Cholecystokinin secretion and gallbladder contraction in patients with celiac sprue. Clin Res, 1983; 31 (5): A836.
    266.   Quigley EMM; Borody TJ; Wienbeck M, et al. Motility of the ileocolonic region in healthy man. Gut, 1983; 24: A1011.
    267.   Borody TJ;  Byrnes D; Kamath  K;  Cook I. Atropine  suppression  test for pancreatic polypeptide-secreting tumours. Digest Dis Sci, 1983; 28: 927.
    268.   Borody TJ; Byrnes D; Henderson L. Small intestinal motility and hormones in the irritable bowel syndrome. 1983; 13: 330.
    269.   Boyle M; Byrnes D; Borody Aust NZ Med TJ, et al. Release of CCK by bombesin and GRP. Aust NZ J Med, 1983; 13: 315.
    270.   Borody TJ; Byrnes D; Boyle M; Best S. Is circulating cholecystokinin a physiological stimulus for pancreatic polypeptide release in man? Digest Dis Sci, 1983; 28: 927.
    271.   Wiley J; Borody TJ; Byrnes D, et al. Cholecystokinin release by magnesium sulphate. Aust NZ J Med, 1983; 13: 330.
    272.   Byrnes D; Borody TJ; Best S; Henderson L. Release of cholecystokinin. Aust Gastro Soc Proc, Melbourne 1982.
    273.   Frommer D; Borody TJ; Maskell A; Mitchell K. Compliance, diagnostic results and costs of a large bowel screening programme, Aust Gastro Soc Proc, Canberra 1982.
    274.   Borody TJ; Daskalopoulos G; Best SP, et al. Cholecystokinin secretion and gallbladder function in patients with coeliac disease. Aust Gastro Soc Proc, Canberra 1982.
    275.   Byrnes D; Borody TJ; Daskalopoulos G, et al. Cholecystokinin and gallbladder contraction: effect of CCK infusion. Peptides, 1982; 2(Suppl 2): 259-62.
    276.   Borody TJ; Byrnes D; Henderson L. Relation of plasma CCK and motilin to gallbladder contraction in man. Aust NZ J Med, 1982; 12: 115.
    277.   Borody TJ; Byrnes D. Plasma cholecystokin, motilin and pancreatic polypeptide and the migrating motor myoelectric complex in man. Aust NZ J Med, 1982; 12: 100.
    278.   Byrnes DJ, Henderson L, Borody TJ; Rehfeld JF. Radioimmunoassay of cholecystokinin in human plasma. Clinica Chimica Acta 111, 1981: 81-9.
    279.   Borody TJ; Byrnes D; Tichen D. Migrating myoelectric complexes and motilin in the dog. J Physiol, 1981; 320: 61-2.
    280.   Daskalopoulos G; Borody TJ; Grant I, et al. Cholecystokinin and gallbladder emptying in normal subjects and patients with gallstones. Proceedings of the Brain/Gut Conference. Florence, 1981; 45.
    281.   Boyle M; Byrnes D; Borody TJ; Henderson L. Effects of food ingestion on plasma bombesin. Proceedings of the Brain/Gut Conference. Florence, 1981; 28.
    282.   Borody TJ; Byrnes D and Henderson L. Plasma Cholecystokinin and the migrating myoelectric complex in man, Proceedings of the Brain/Gut Conference, Florence, 1981; 27.
    283.   Gude RA; Stokes J; Borody TJ. Myasthenia gravis in Melanesians in the Solomon Islands. PNG Med J, 1981; 24 (1): 50-3.
    284.   Borody TJ; Byrnes D; Slowiaczek J; Titchen D. Effect of motilin antiserum on porcine IDMCS. Reg Peptides, 1981; (suppl): S13.
    285.   Borody TJ; Byrnes D; Slowiaczek J; Titchen D.  Immunoneutralisation of motilin.  T.  Horm Metabol Res, 1981; 13 (8): 470-1.
    286.   Borody TJ; Byrnes D; Slowiaczek J; Titchen D. Motilin and migrating myoelectric complexes in pigs. J Physiol, 1981; 310; 37-8.
    287.   Byrnes DJ; Henderson L; Borody TJ; Rehfeld JF. Radioimmunoassay of cholecystokinin in human plasma. Clin Chem Acta, Volume III 1981; (1): 81-9.
    288.   Byrnes D; Borody TJ and Henderson L. Plasma cholecystokin Reg Peptides I, (Suppl): S15.
    289.   Byrnes D; Henderson L; Borody TJ; Rehfeld JH. Radioimmunoassay of cholecystokinin. Aust NZ J Med, 1980; 10: 365.
    290.   Borody TJ; Byrnes D; Henderson L. Effect of renal function and age on plasma motilin and pancreatic polypeptide. Aust NZ J Med, 1980; 10: 365.
    291.   Borody TJ; Byrnes D; Henderson L. In-vitro release of motilin for human duodenal mucosa. Aust NZ J Med, 1980; 10: 365.
    292.   Borody TJ; Byrnes D; Henderson L. Mechanisms of motilin release by metoclopramide. Reg Peptides I, 1980; (Suppl 1): S13.
    293.   Byrnes D; Henderson L; Meredith C; Borody TJ. Release of motilin by metoclopramide. Aust NZ J Med, 1980; 10: 109.
    294.   Borody TJ; Byrnes D; Slowiaczek J; Titchen D. Effect of Motilin antiserum infusion on Porcine IDMCS. Reg Peptides, 1980; 1 (S1): S13.
    295.   Borody TJ; Chinwah PM; Graham GG, et al. Chlorbutol toxicity and dependence.  Med J Aust, 1979; 1 (7): 288.
    296.   Borody TJ; Dickson MR; Wilhelm DL. Inflammatory response in chemical injury in liver. Proce Soc Aust Exp pathologists, 1971 Canberra.

    Book Chapters

    1.         Borody TJ. (2019) Fecal Microbiota Transplantation – Treatment of Gut Microbiome. In: “Gut Microbiome – Gastrointestinal Diseases and Their Associated Infections”. Eslick GD, (ed). Publishing ELSEVIER; 249-57.

    2.         Borody TJ; Leis S; Pang G; Wettstein AR. (2016) Fecal bacteriotherapy in the treatment of recurrent C. difficile infection. In: UpToDate, Rutgeerts P and Grover S. (eds), Walters Kluwer publishing

    3.         Borody TJ, Campbell J. (2012) Gut Microbiota-Brain Connection. Arranga T, Viadro CI, Underwood L (eds) in: Bugs, Bowel & Behaviour: The Ground-Breaking Story of the Gut-Brain Connection. Arranga T (ed) New York USA, Skyhorse Publishing.

    4.         Borody TJ, Campbell J. (2012) Fecal Microbiota Transplantation: Techniques, Applications and Issues. In Gerald Freidman (ed) Gastroenterology Clinics of North America Clinical Applications of Probiotics in Gastroenterology: Questions and Answers, (pp. 781-803) Philadelphia USA, Elsevier

    5.         Borody TJ; Leis S; Pang G; Wettstein AR. (2006) Fecal bacteriotherapy in the treatment of recurrent C. difficile infection. In: UpToDate, Rose, BD (ed), Waltham

    6.         Borody TJ; Conway PL; Koch TR. (2003) Probiotics and the Colon: Therapeutic and Prophylactic Uses. (ed) In: Colonic Diseases. Humana Press: 141-61.

    7.         Borody TJ; Clancy R; Warren EF et al. (2002) Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites. RH Hunt, GNJ Tytgat (eds) In; Helicobacter pylori: Basic Mechanisms to Clinical Cure Maui: 373-82.

    8.         Borody, TJ; Pang G; Clancy R; Ren Z. (2002) IgG2 Anti-H. Pylori antibody assay for the diagnosis of ‘high cancer risk’ H. pylori infection. RH Hunt, GNJ Tytgat (eds) In: Helicobacter pylori: Basic Mechanisms to Clinical Cure.

    9.         Clancy R; Borody TJ; Ren Z; Pang G. (2002) Can the response to eradication therapy in helicobacter pylori infection be predicted? RH Hunt, GNJ Tytgat (eds), In: Helicobacter pylori: Basic Mechanisms to Clinical Cure.

    10.      Borody TJ. (2000) Quadruple should be first-line therapy for Helicobacter pylori infection. Hunt RH, Tytgat GNJ (eds) In: Helicobacter Pylori-Basic Mechanisms to Clinical Cure; Chapter 67:623-9.

    11.      Clancy R; Borody TJ. (2000) What role for clarithromycin in the treatment of Helicobacter pylori infection? Hunt RH, Tytgat GNJ (eds) In: Helicobacter pylori – Basic Mechanisms to Clinical Cure; Chapter 63: 587-91.

    12.      Borody TJ. A man with dyspepsia, Patient Management (Case Book), 1997; 26: 83.

    13.      Borody TJ; Shortis NP. (1996) Treatment of Patients with failed eradication – a personal view. Hunt RH, Tytgat GNJ (eds) In: Helicobacter pylori – Basic Mechanisms to Clinical Cure; Chapter 36; 357-65.

    14.      Borody TJ; Shortis NP; Chongnan J et al. (1996) Practical, Optimal Quad H. pylori Eradication Program for First-Line & Eradication Failure (EF) Patients. RH Hunt, GNJ Tytgat (eds) In: Helicobacter pylori: Basic Mechanisms to Clinical Cure, Ottawa.

    15.      Borody TJ. (1992) Diarrhoea – Acute and Chronic. Speight TM (eds) In: MIMS Disease Index, Singapore, Kyodo Printing Co P/L.

    16.      Borody TJ; Brandl S; Andrews P. (1991) Adverse effects of Triple Therapy. Recent Advances in Chemotherapy: proceedings of the 17th International Congress of Chemotherapy, Ed by I D Adamas, H Lode and E Rubenstein In: Futuramed-Verl Berlin, Munich: 632-3.

    17.      Borody TJ and Carrick J. (1991) Long-term Campylobacter pylori recurrence following apparent eradication. Bio-Medical Division F Megraud & H Lamouliatte, Editors. Elsevier Science Publishers

    18.      Carrick J; Daskalopoulos G; Borody TJ. (1987) Ethnic differences in the prevalence of Campylobacter pyloridis infection. Peterson WL (ed) In: Campylobacter pylori: a Multi-Disciplinary Workshop, Colorado USA.

    Books

    1.         Borody T; Peek R and Rosendahl C. Handbook of Obstetrics and Gynaecology. Dai

    Nippon Press, Hong Kong 1975.

It just takes courage and takes, years and years of perseverance to change paradigms.

See all Professor Borody’s research papers and awards here ORCID ID

ABC news report about Professor Borody

For conference organisers & media

Download hi-res image of Professor Borody